A case of renal cell carcinoma with late recurrence in the bilateral hilar lymph nodes twenty years after surgery

Yusuke Sakurai\textsuperscript{a,}\textsuperscript{*}, Hiroyuki Matsuura\textsuperscript{a}, Yuri Oshima\textsuperscript{a}, Kaho Hirai\textsuperscript{a}, Eriko Tani\textsuperscript{a}, Naoki Yoshimoto\textsuperscript{a}, Kenichi Minami\textsuperscript{a}, Kenichi Wakasa\textsuperscript{b}, Tomonori Hirashima\textsuperscript{c}

\textsuperscript{a} Department of Respiratory Medicine, Ishikiriseiki Hospital, Osaka, Japan
\textsuperscript{b} Department of Pathology, Ishikiriseiki Hospital, Osaka, Japan
\textsuperscript{c} Department of Thoracic Oncology, Ishikiriseiki Hospital, Osaka, Japan

\textbf{ARTICLE INFO}

\textbf{Keywords:}
Renal cell carcinoma
Late recurrence
Bilateral hilar lymph nodes

\begin{abstract}
Renal cell carcinoma (RCC) is a common malignancy with a high recurrence rate. However, brain and bilateral hilar lymph node (BHL) relapse is rare. A 65-year-old man with a chief complaint of hemosputum visited the primary care clinic. Computed tomography revealed BHL enlargement. Histopathological examination of biopsy specimens from the left lingular bronchus revealed RCC. This finding was similar to that of a left nephrectomy specimen of RCC observed 20 years ago. If patients have a medical history of RCC, physicians should consider the possibility of RCC recurrence, regardless of the number of years elapsed postoperatively.
\end{abstract}

1. Introduction

Renal cell carcinoma (RCC) is a common malignancy and represents 2–3% of all adult cancers \cite{1}. Postsurgical recurrence occurs in 20–30\% of patients with localized RCC \cite{2}. Cases of relapse 10 years after initial nephrectomy have been observed in 4.7–11\% of patients with RCC \cite{3,4}. Patients with RCC commonly experience delayed distant metastasis in the lungs, bone, and liver 10 years after nephrectomy \cite{5}. Brain and bilateral hilar lymph nodes (BHL) are rare relapse sites of RCC. Herein, we report a case of RCC with an extremely delayed relapse in both the brain and BHL 20 years after radical nephrectomy. A medical history of RCC warrants close attention from the physician to assess the recurrence of RCC.

2. Case report

A 65-year-old man with a chief complaint of hemosputum visited a primary care clinic. Computed tomography (CT) was performed, which revealed enlargement of the BHL. The patient was referred to our hospital in November 20XX. He had been receiving hemodialysis for renal failure due to a polycystic kidney from 20XX-22 and underwent radical left nephrectomy with a diagnosis of RCC on 20XX-20, with no recurrence during follow-up. At the first visit, physical examination did not reveal any remarkable findings. Laboratory data did not show any abnormalities other than those due to hemodialysis (Table 1). As shown in Fig. 1, chest X-ray and CT scan revealed enlargement of the BHL with accumulation of fluorodeoxyglucose-positron emission tomography (FDG-PET) (Fig. 1-C). On CT (Fig. 1-D), a single small nodule was located in the left upper lobe without any tracer accumulation on FDG-PET. Magnetic

\begin{table}[h]
\centering
\begin{tabular}{|c|c|c|}
\hline
\textbf{Keyword} & \textbf{Definition} & \textbf{Abbreviation} \\
\hline
Renal cell carcinoma & A type of cancer that starts in the kidneys & RCC \\
Late recurrence & Recurrence of a disease after a period of remission & \textsuperscript{1} \\
Bilateral hilar lymph nodes & Lymph nodes located in the hilum of the lung & BHL \\
\hline
\end{tabular}
\caption{List of abbreviations.}
\end{table}

\textsuperscript{1} Corresponding author.
\textsuperscript{*} E-mail address: y-sakurai@ishikiriseiki.or.jp (Y. Sakurai).

https://doi.org/10.1016/j.rmcr.2022.101617
Received 31 January 2022; Received in revised form 16 February 2022; Accepted 17 February 2022
Available online 22 February 2022
2213-0071/© 2022 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license
(www.elsevier.com/locate/rmcr).
Respiratory Medicine Case Reports 36 (2022) 101617

2-B). Based on these imaging findings, we attempted to perform an endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) of the left hilar lymph node in November 20XX. However, because we found an intrabronchial mass that occluded the left lingular bronchus, we performed transbronchial direct biopsy (Fig. 3).

Histopathological findings from the biopsy specimens revealed clear cytoplasmic cells with a sinusoidal vascular network (Fig. 4-A). Immunohistochemical staining was positive for PAX8 and vimentin (Fig. 4-B, 4-C). Immunohistochemistry also revealed the following: AE1/AE3(+), CAM5.2(+), CD10(+), Naptin A(−), and TTF-1(−). The patient was diagnosed with extremely late recurrence of a clear cell type RCC. We confirmed that the finding was the same as that (Fig. 4-D) of the left nephrectomy specimen obtained on 20XX-20. The patient was transferred to a specialized facility for maintenance dialysis and renal cancer treatment. Brain radiotherapy and the combination anti-cancer therapy of avelumab and axitinib was initiated immediately.

3. Discussion

A recurrence developing for more than 10 years after the complete removal of the primary tumor is referred to as late recurrence [6].

The patient described herein experienced recurrence of BHL, lung, and brain metastases after a 20-year latent period. In a previous study [7], among 707 patients who underwent nephrectomy for RCC, the first relapse was reported to occur in the lungs (46.7%), bone (17.8%), retroperitoneal organs (11.1%), liver (6.7%), mediastinal lymph node (4.4%), and brain (2.2%). Miyao et al. [4] reported that among 470 patients who had undergone curative treatment of RCC and had not developed recurrence within 10 years of follow-up, 30 had developed late recurrence at 44 sites, including the lungs (36.4%), kidney (25%), and bone (13.6%), followed by the brain, pancreas, adrenal gland, lymph nodes, and liver.

To the best of our knowledge, there is no report of extremely late recurrence of RCC in both the BHL and brain 20 years after radical nephrectomy.

BHL enlargement is an important radiographic finding, and its incidence is reported to be 3–40 per 100,000 studies [8]. A previous study reported that the most common disease in 78 patients with bilateral and/or mediastinal lymphadenopathy diagnosed using EBUS-TBNA was sarcoidosis (73%), followed by lymphoma (10%) and reactive lymphadenopathy (10%); non-lymphoma malignancy was found in one case only [9]. This study speculated that RCC with BHL enlargement is extremely rare. In that study, lymph adenopathy was diagnosed by EBUS-TBNA in 92.3% of the cases [9]. Hence, EBUS-TBNA is an extremely useful modality for the diagnosis of BHL enlargement. The previous studies speculated two metastatic routes of RCC to the mediastinal hilar lymph node [10, 11]. One route [10] is through the retroperitoneal lymph node to the pulmonary ligament lymph node. The other route [11] is through the thoracic duct. Subsequently, malignant cells invading the retroperitoneal lymph node or the thoracic duct would settle in the mediastinal hilar lymph nodes.

The concept of tumor dormancy [12–14] is considered as a mechanism for late recurrence. Dormancy is thought to occur especially often in RCCs and cutaneous malignant melanomas [6] and is the stagnation of the cell cycle due to the non-proliferative phase of cancer cells and the extension of the quiescent phase [6]. It is speculated that the balance between immune function and tumor growth leads to dormancy [15]. It is thought that a decrease in immune function would trigger a reactivation in dormant lesions, which would subsequently appear as metastasis [16]. In this case, as the immune system declined with aging, RCC metastasis would have appeared.

A medical history of RCC thus warrants close attention from not only urologists but also the physician to assess the recurrence of RCC, regardless of the number of years after the surgery, even if the organ is the BHL, which is unlikely to be a relapse site of RCC. Physicians should maximally try to obtain the specimen from the organ for accurate diagnosis.

| Table 1 | Laboratory test on first visit. |
|---------|--------------------------------|
| **Blood count** | **Biochemical test** |
| White blood cell (μL) | 4490 | Aspartate aminotransferase (IU/L) | 8 |
| Neutrophil (μL) | 3228 | Alanine aminotransferase (IU/L) | 6 |
| Lymphocyte (μL) | 561 | Lactate dehydrogenase (U/L) | 15 |
| Eosinophil (μL) | 327 | Total bilirubin (mg/dL) | 0.3 |
| Basophil (μL) | 31 | Total protein (g/dL) | 7.1 |
| Red blood cell (x 10^6/μL) | 285 | Blood urea nitrogen (mg/dL) | 38.5 |
| Hemoglobin (g/dL) | 9.2 | Creatinine (mg/dL) | 9.10 |
| Platelet (x 10^9/μL) | 20.6 | Sodium (mEq/L) | 138 |
| Hemostasis test | | Potassium (mEq/L) | 4.4 |
| Prothrombin time (sec) | 11.7 | Chloride (mEq/L) | 100 |
| APTT (sec) | 28.8 | C-reactive protein (mg/dL) | 0.84 |
| PT-INR | 1.11 | **Tumor marker** |
| | | CEA (ng/mL) | 1.5 |
| | | CYFRA (ng/mL) | 7.7 |
| | | ProGRP (pg/mL) | 277.0 |

APTT: Activated partial thromboplastin time; PT-INR: Prothrombin time-international normalized ratio.
CEA: Carcino Embryonic Antigen; Cyfra: CYFRA: Cytokeratin-19 Fragment; ProGRP: Pro-Gastrin-Releasing-Peptide.
4. Conclusion

1) We reported a case of RCC with an extremely delayed relapse in both the brain and BHL 20 years after radical nephrectomy.
2) As the immune system declined with aging, dormant RCC metastasis would have appeared.
3) A medical history of RCC warrants close attention from not only urologists but also the physician to assess the recurrence of RCC, regardless of the number of years after the surgery, even if the organ is BHL, which is unlikely to be relapse site of RCC.

Ethics approval and consent to participate

We obtained written informed consent to publish the information, including the laboratory data and image findings, from the patient’s family since the patient had already died at the time of writing this case report. Furthermore, this case report was approved by the Institutional Review Board of Ishikiriseiki Hospital on October 20, 2021 (approval number: 21–36).
Author contributions

Y.S., K.M., and T.H. conceived the outline plans. All authors contributed to the data interpretation. K.W. diagnosed the pathological findings. All authors read and critically reviewed the manuscript drafts. All authors have approved the final manuscript.

**Fig. 3.** shows an intrabronchial mass occluding the left lingular bronchus.

**Fig. 4.** Histological staining of specimens from the right hilar lymph node (A–C) and resected specimen of renal cell carcinoma (RCC) (D). (A) A photomicrograph of hematoxylin and eosin (H&E) staining of the endoscopic direct biopsy specimen reveals clear cytoplasmic cells mediated by a sinusoidal vascular network (magnification, x100). (B) Immunohistochemistry staining of the lymph node specimen showing positive PAX 8 (magnification, x100). (C) Immunohistochemistry staining of the lymph node showing positive vimentin (magnification, x100). (D) A photomicrograph of the H&E-stained resected specimen of RCC (magnification, x100).
Declarations of competing interest

None.

Acknowledgments

The authors thank the patient and his family. The authors also extend their appreciation to Physician-in-charge (Ishinkai-Yao-Sogo Hospital) who lent us pathological specimens and specimen-embedded paraffin block. The authors thank Editage (www.editage.jp) for English language editing.

References

[1] R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2020, CA A Cancer J. Clin. 70 (2020) 7–30, https://doi.org/10.3322/caac.21590.
[2] P.L. Crispen, R.H. Breau, C. Allmer, C.M. Lohse, J.C. Cheville, B.C. Leibovich, M.L. Blute, Lymph node dissection at the time of radical nephrectomy for high-risk clear cell renal cell carcinoma: indications and recommendations for surgical templates, Eur. Urol. 59 (2011) 18–23, https://doi.org/10.1016/j.eururo.2010.08.043.
[3] E. Nakano, H. Fujioka, M. Matsuda, M. Osafune, M. Takaha, T. Sonoda, Late recurrence of renal cell carcinoma after nephrectomy, Eur. Urol. 10 (1984) 347–349, https://doi.org/10.1159/000463826.
[4] N. Miyao, S. Naito, S. Ozono, N. Shinohara, N. Masumori, T. Igarashi, M. Nakao, T. Tsushima, Y. Senga, S. Horie, H.O. Kanayama, N. Tokuda, M. Kobayashi, Japanese Society of Renal, Late recurrence of renal cell carcinoma: retrospective and collaborative study of the Japanese Society of Renal Cancer, Urology 77 (2011) 379–384, https://doi.org/10.1016/j.urology.2010.07.462.
[5] Y. Fukushima, G. Yoshikawa, M. Takasago, S. Shimizu, K. Tsutsui, Extremely delayed multiple brain metastases from renal cell carcinoma: remission achieved with total surgical removal: case report and literature review, World Neurosurg 92 (2016), https://doi.org/10.1016/j.wneu.2016.05.065, 583.e13–583.e17.
[6] S. Friberg, A. Nyström, Cancer metastases: early dissemination and late recurrences, Cancer Growth Metastasis 8 (2015) 43–49, https://doi.org/10.4137/CGM.S31244.
[7] M. Muramoto, I.J.-I. Iwamura Masatsugu, Baba Shiro, An optimal follow-up protocol for renal cell carcinoma based on the occurrence of recurrence after surgery, https://www.jstage.jst.go.jp/article/jpnjurol1989/91/12/91_12_700/_pdf/-char/ja, 2000. (Accessed 10 December 2021).
[8] P.L. Carr, D.E. Singer, P. Goldenheim, J. Bernardo, A.G. Mulley, Noninvasive testing of asymptomatic bilateral hilar adenopathy, J. Gen. Intern. Med. 5 (1990) 138–146, https://doi.org/10.1007/BF02600516.
[9] Z. Boujaoude, M. Dahdel, M. Pratter, J. Kass, Endobronchial ultrasound with transbronchial needle aspiration in the diagnosis of bilateral hilar and mediastinal lymphadenopathy, J. Bronchology Interv. Pulmonol. 19 (2012) 19–23, https://doi.org/10.1097/LBR.0b013e3182442b89.
[10] F.W. Wright, Enlarged hilar and mediastinal nodes (and especially lower right hilar node enlargement) as a sign of metastasis of a renal tumour, Clin. Radiol. 28 (1977) 431–436, https://doi.org/10.1016/s0009-2660(77)80159-1.
[11] J. Assouad, M. Riquet, C. Foucault, G. Hidden, V. Delmas, Renal lymphatic drainage and thoracic duct connections: implications for cancer spread, Lymphology 39 (2006) 26–32.
[12] L. Holmgren, M.S. O’Reilly, J. Folkman, Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression, Nat. Med. 1 (1995) 149–153, https://doi.org/10.1038/nm0295-149.
[13] J.A. Aguirre-Ghiso, Models, mechanisms and clinical evidence for cancer dormancy, Nat. Rev. Cancer 7 (2007) 834–846, https://doi.org/10.1038/nrc2256.
[14] H.F. Wang, S.S. Wang, M.C. Huang, X.H. Liang, Y.J. Tang, Y.L. Tang, Targeting immune-mediated dormancy: a promising treatment of cancer, Front. Oncol. 9 (2019) 498, https://doi.org/10.3389/fonc.2019.00498.
[15] M. Al-Tameemi, M. Chaplain, A. d’Onofrio, Evasion of tumours from the control of the immune system: consequences of brief encounters, Biol. Direct 7 (2012) 31, https://doi.org/10.1186/1745-6150-7-31.
[16] J.M. Cozar, N. Apostolou, M. Tallada, F. Garrido, F. Ruiz-Cabello, Late pulmonary metastases of renal cell carcinoma immediately after post-transplantation immunosuppressive treatment: a case report, J. Med. Case Rep. 2 (2008) 111, https://doi.org/10.1186/1752-1947-2-111.